Survodutide (BI 456906) is an investigational dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. It combines the appetite-suppressing effects of GLP-1 agonism with glucagon's energy-expenditure and hepatic fat-burning properties. It is in Phase III clinical trials for obesity and MASH (fatty liver disease).

How effective is survodutide for weight loss?

In the Phase II trial, the highest dose group (6.0 mg weekly) achieved 18.7% body weight loss over 46 weeks. Weight loss curves had not yet plateaued, suggesting additional weight loss with longer treatment. This positions survodutide between semaglutide (~15%) and retatrutide (~24%) in efficacy.

Is survodutide good for fatty liver disease?

Survodutide has shown exceptional results for MASH (formerly NASH). In Phase II trials, 83% of patients on the highest dose achieved MASH resolution, and liver fat content decreased by 72-87%. The glucagon component directly drives hepatic fat oxidation, which may explain the superior liver results compared to GLP-1-only drugs.

How is survodutide different from tirzepatide?

Both are dual-agonist drugs, but they target different receptor pairs. Tirzepatide targets GLP-1 + GIP receptors, while survodutide targets GLP-1 + glucagon receptors. The glucagon component in survodutide increases energy expenditure and drives hepatic fat oxidation, potentially offering superior benefits for liver fat reduction, while tirzepatide may produce greater overall weight loss.

When will survodutide be available?

Survodutide is currently in Phase III clinical trials (SYNCHRONIZE program for MASH, ACHIEVE program for obesity). If results are positive, FDA submission could occur in 2027-2028, with potential approval in 2028-2029. It is not currently available by prescription.

What are the main side effects of survodutide?

The most common side effects are gastrointestinal: nausea (41-67%), diarrhea (17-29%), vomiting (15-28%), and constipation (8-15%). Most GI events are mild to moderate and decrease over time. Small heart rate increases (~3-5 bpm) and transient liver enzyme elevations have also been observed. Slow dose escalation is important for tolerability.

Survodutide: GLP-1/Glucagon Dual Agonist — Results & Dosage

Survodutide: The GLP-1/Glucagon Dual Agonist Approach

Survodutide (BI 456906) is a dual glucagon and GLP-1 receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. While tirzepatide combines GLP-1 with GIP agonism, survodutide takes a fundamentally different dual-agonist approach by pairing GLP-1 with glucagon receptor activation. This distinction matters because glucagon brings a metabolic toolkit that GIP does not — particularly increased energy expenditure and potent liver fat reduction. This article is for educational purposes only; consult a physician before starting any medication.

The SYNCHRONIZE trial program has produced weight loss data competitive with tirzepatide and semaglutide, but survodutide's most distinctive asset may be its effects on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). For a direct comparison with tirzepatide, see our survodutide vs tirzepatide analysis.

Mechanism of Action: Why GLP-1 + Glucagon?

Survodutide simultaneously activates two receptors with carefully calibrated relative potency:

GLP-1 Receptor Agonism

The GLP-1 component provides the appetite-suppressing, insulin-sensitizing foundation shared by semaglutide and tirzepatide. It slows gastric emptying, enhances beta-cell function, and reduces food intake through hypothalamic signaling.

Glucagon Receptor Agonism

The glucagon component is what makes survodutide distinctive^[1]:

Increased energy expenditure. Glucagon promotes thermogenesis, raising resting metabolic rate. Studies show glucagon infusion can increase resting energy expenditure by 150-200 kcal/day. This means survodutide may promote weight loss through both reduced intake (GLP-1) and increased burn (glucagon).
Hepatic lipid oxidation. Glucagon drives the liver to burn fat, reducing hepatic steatosis. This makes survodutide particularly promising for MASH.
Amino acid metabolism. Glucagon stimulates amino acid catabolism and ureagenesis.
Reduced lipogenesis. Glucagon inhibits de novo fatty acid synthesis in the liver.

The GLP-1 component counterbalances glucagon's hyperglycemic effect, maintaining glycemic stability while capturing glucagon's metabolic benefits.

SYNCHRONIZE Trial Results

Weight Loss (Phase 2)

The Phase 2 trial in adults with overweight/obesity (BMI 28-50) demonstrated significant weight loss across dose groups over 46 weeks^[2]:

Dose (Weekly)	Weight Loss at 46 Weeks	Subjects Achieving 10% or more
Placebo	-2.8%	12%
0.6 mg	-6.2%	32%
2.4 mg	-12.5%	58%
3.6 mg	-13.2%	62%
4.8 mg	-14.9%	72%
6.0 mg (max escalated)	-18.7%	83%

The headline result — 18.7% mean weight loss at the highest dose over 46 weeks — is clinically significant. Weight loss curves had not plateaued, suggesting continued weight loss with longer treatment duration.

MASH Data: Where Survodutide Stands Out

Survodutide's most differentiated clinical story is in MASH. In a dedicated Phase 2 study of biopsy-confirmed MASH patients^[3]:

83% of patients achieved MASH resolution at the highest dose (vs 18% placebo)
52-64% achieved fibrosis improvement by at least one stage
Liver fat content decreased by 72-87% across dose groups

These results are competitive with or superior to resmetirom (Rezdiffra), the first FDA-approved MASH treatment, and surpass what GLP-1-only agonists have demonstrated.

How Survodutide Compares

Feature	Semaglutide	Tirzepatide	Survodutide	Retatrutide
Mechanism	GLP-1	GLP-1 + GIP	GLP-1 + Glucagon	GLP-1 + GIP + Glucagon
Peak Weight Loss	~15%	~22.5%	~18.7%	~24.2%
MASH Efficacy	Moderate	Good	Exceptional (83%)	Pending data
Energy Expenditure	Minimal	Minimal	Significant (glucagon)	Significant (glucagon)
Developer	Novo Nordisk	Eli Lilly	Boehringer Ingelheim	Eli Lilly
FDA Status	Approved	Approved	Phase III	Phase III

For a deeper comparison, see our survodutide vs tirzepatide comparison and semaglutide vs survodutide comparison.

Side Effects and Safety

Survodutide's side-effect profile is consistent with the GLP-1 agonist class:

Nausea: 41-67% (dose-dependent; most common during escalation)
Diarrhea: 17-29%
Vomiting: 15-28%
Constipation: 8-15%
Heart rate increase: Small mean increase (~3-5 bpm)
Transaminase elevations: ALT increases observed, generally transient

The discontinuation rate due to adverse events was 12-24% across dose groups. Slow dose escalation appears critical for tolerability. Glycemic parameters improved across all dose groups despite the glucagon component.

Dosing and Titration Protocol

Survodutide is administered as a once-weekly subcutaneous injection. The Phase 2 titration schedule was:

Weeks 1-4: 0.3 mg weekly
Weeks 5-8: 0.6 mg weekly
Weeks 9-12: 1.2 mg weekly
Weeks 13-16: 2.4 mg weekly
Weeks 17-20: 3.6 mg weekly
Weeks 21-24: 4.8 mg weekly
Weeks 25+: 6.0 mg weekly (if tolerated)

For general principles on dose escalation, see our peptide dosage guide.

Development Timeline and Market Outlook

Boehringer Ingelheim is advancing survodutide through an extensive Phase 3 program:

SYNCHRONIZE program: Phase III trials in patients with MASH and fibrosis
ACHIEVE program: Phase III trials in adults with obesity
Type 2 diabetes: Phase III trials ongoing

If Phase III results confirm Phase II data, FDA submission could occur in 2027-2028. The MASH indication may be survodutide's fastest path to market, given the limited competition and the strength of its Phase 2 liver data.

Relevance to the Peptide Community

For those interested in metabolic optimization through peptides, several parallels exist:

Fat metabolism: AOD-9604 and tesamorelin both target fat reduction through non-appetite pathways, similar to survodutide's glucagon component
Liver health: BPC-157 has been studied for liver protection in preclinical models
GH axis: CJC-1295 + ipamorelin stacks aim to optimize body composition through GH secretion
Metabolic optimization: Our weight-loss peptides overview covers the full spectrum

The Bottom Line

Survodutide represents a genuinely differentiated approach to obesity and metabolic disease. While the market is crowded with GLP-1 agonists and GLP-1/GIP dual agonists, survodutide's glucagon component provides unique metabolic benefits — particularly increased energy expenditure and potent liver fat reduction — that existing therapies cannot match. Its strongest card may be the MASH indication, where glucagon-mediated liver fat reduction gives it an advantage that pure GLP-1 approaches cannot replicate.